The Pharma-Regulatory Revolving Door
The guest exposes the lack of safeguards between big pharma and regulatory agencies like the FDA and CDC, where executives routinely move between pharmaceutical companies and government health bodies. This creates a conflict of interest that prioritizes profit over public health and suppresses criticism of drugs like SSRIs.
- No safeguards prevent pharma execs from joining the FDA and vice versa
- This creates a 'revolving door' that benefits pharmaceutical profits
- Criticism of SSRIs is dismissed as 'anti-science' by those with industry ties
- Pharma influence extends to media, medical education, and politics
“There's basically just a constant revolving door in Washington DC with executives at companies like Pfizer then going to work for the FDA and vice…”